ファブリー病治療市場：治療タイプ、薬剤、投与経路別-2025-2030年の世界予測

ファブリー病治療市場は、2023年に25億米ドルと評価され、2024年には27億1,000万米ドルに達すると予測され、CAGR 8.47％で成長し、2030年には44億1,000万米ドルに達すると予測されています。

ファブリー病治療市場の対象範囲には、この稀な遺伝性リソソーム貯蔵障害の症状を管理し、疾患の進行を遅らせることを目的とした治療ソリューションが含まれます。これには、酵素補充療法、シャペロン療法、基質低減療法、潜在的には遺伝子療法が含まれ、市場は特殊医薬品やバイオテクノロジーの革新にまで広がっています。効果的なファブリー病治療の必要性は、疼痛、腎不全、心臓合併症などの重篤な症状を緩和し、患者のQOLを大幅に向上させる必要性から生じています。これらの治療法は、病院、専門治療センター、在宅医療の現場で応用されており、最終用途には、この病気に罹患している小児患者と成人患者の両方が含まれます。市場の洞察によれば、診断法の改善による有病率の上昇、早期介入を促進する患者意識の高まり、治療選択肢の拡大を目指す大手バイオ医薬品企業による研究開発への多額の投資などが、主要な成長要因となっています。さらに、希少疾病用医薬品に対する規制上の優遇措置がこの市場のイノベーションを促進しています。

遺伝子治療と個別化医療の進歩に潜在的なビジネスチャンスがあり、変革的な治療法を提供します。時宜を得た提言としては、戦略的協力関係を活用し、治療効果と患者の転帰を高めるために実世界のデータ収集に注力することが挙げられます。しかし、高額な治療費、限られた患者数、厳格な規制要件といった課題が、市場の成長に制約をもたらしています。さらに、希少疾患治療の承認や償還政策が予測不可能であることも、市場力学をさらに複雑にしています。イノベーションと研究は、治療レジメンの最適化と、ナノ粒子やCRISPRベースのソリューションなどの新規ドラッグデリバリー技術の開発に軸足を置き、バイオアベイラビリティの向上と副作用の軽減を目指すべきです。ファブリー病治療市場は、ニッチなマーケティング戦略を必要とし、科学的ブレークスルーを活用するために継続的な臨床開発を行う環境を醸成する、その特殊性が特徴です。

市場力学：急速に進化するファブリー病治療市場の主要市場インサイトを公開

ファブリー病治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ファブリー病の治療法としてのメッセンジャーRNAに対する需要の高まり
  • 臨床試験数の増加
  • 遺伝性疾患の罹患率の増加と認知度の向上
• 市場抑制要因
  • ファブリー病の治療に関する進歩に対する認識不足
• 市場機会
  • ファブリー病治療のための継続的な研究開発
  • 新興国におけるヘルスケア支出の増加とインフラの改善
• 市場の課題
  • 特定の国における新技術導入の制限

ポーターの5つの力：ファブリー病治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ファブリー病治療市場における外部からの影響の把握

外部マクロ環境要因は、ファブリー病治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ファブリー病治療市場における競合情勢の把握

ファブリー病治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスファブリー病治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ファブリー病治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ファブリー病治療市場における成功への道筋を描く

ファブリー病治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ファブリー病の治療法としてメッセンジャーRNAの需要が増加
    • 臨床試験の増加
    • 遺伝性疾患の発生率増加と意識の高まり
  • 抑制要因
    • ファブリー病の治療に関する進歩についての認識不足
  • 機会
    • ファブリー病の治療のための継続的な研究開発
    • 新興国におけるヘルスケア費の増加とインフラの改善
  • 課題
    • 特定の国における新技術導入の制限
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ファブリー病治療市場治療の種類別

• シャペロン治療
• 酵素補充療法
• 臓器特異的治療
• 基質還元療法

第7章 ファブリー病治療市場薬物別

• アガルシダーゼベータ
• ミガラスタット
• パイプライン医薬品

第8章 ファブリー病治療市場：投与経路別

• 静脈内
• オーラル

第9章 南北アメリカのファブリー病治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のファブリー病治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのファブリー病治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amicus Therapeutics Inc.
• Avrobio Inc.
• BioMarin
• Biosidus S.A.
• Digestive Care, Inc.
• GlaxoSmithKline PLC
• Idorsia Pharmaceuticals Ltd.
• ISU Abxis Co Ltd.
• JCR Pharmaceuticals Co Ltd.
• Leadiant Biosciences, Inc.
• Nestle Health Science
• Pfizer Inc.
• Protalix Biotherapeutics Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. FABRY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FABRY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FABRY DISEASE TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORGAN-SPECIFIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY MIGALASTAT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PIPELINE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Fabry Disease Treatment Market was valued at USD 2.50 billion in 2023, expected to reach USD 2.71 billion in 2024, and is projected to grow at a CAGR of 8.47%, to USD 4.41 billion by 2030.

The scope of the Fabry disease treatment market encompasses therapeutic solutions aimed at managing symptoms and slowing disease progression for this rare genetic lysosomal storage disorder. This includes enzyme replacement therapies, chaperone therapies, substrate reduction therapies, and potentially gene therapies, with the market extending to specialty pharmaceuticals and biotechnological innovations. The necessity for effective Fabry disease treatments stems from the need to alleviate severe symptoms such as pain, renal failure, and cardiac complications, significantly improving patients' quality of life. These treatments find application across hospitals, specialized treatment centers, and homecare settings, with end-use scope including both pediatric and adult patient populations affected by the disease. Market insights reveal key growth factors including increasing prevalence rates owing to improved diagnostics, heightened patient awareness facilitating early intervention, and substantial R&D investments from major biopharmaceutical companies aiming to expand therapeutic options. Moreover, regulatory incentives for orphan drugs foster innovation within this market.

Potential opportunities lie in the advancement of gene therapy and personalized medicine, offering transformative treatment modalities. Timely recommendations include leveraging strategic collaborations and focusing on real-world data collection to enhance therapeutic efficacy and patient outcomes. However, challenges such as high treatment costs, limited patient populations, and rigorous regulatory requirements pose constraints on market growth. Furthermore, the unpredictable nature of rare disease treatment approvals and reimbursement policies further complicate market dynamics. Innovation and research should pivot towards optimizing treatment regimens and developing novel drug delivery technologies, such as nanoparticle and CRISPR-based solutions, to improve bioavailability and reduce adverse effects. The Fabry disease treatment market is characterized by its specialized nature, necessitating niche marketing strategies and fostering an environment of continuous clinical development to capitalize on scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fabry Disease Treatment Market

The Fabry Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for messenger RNA as a treatment modality for Fabry disease
  • Increasing number of clinical trials
  • Growing incidences of genetic disorders and increasing awareness
• Market Restraints
  • Lack of awareness about advancements with respect to treatments for Fabry disease
• Market Opportunities
  • Ongoing research and development for the treatment of Fabry disease
  • Increasing healthcare expenditure and improving infrastructure in emerging economies
• Market Challenges
  • Limitations in adopting new technologies in certain countries

Porter's Five Forces: A Strategic Tool for Navigating the Fabry Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fabry Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fabry Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fabry Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fabry Disease Treatment Market

A detailed market share analysis in the Fabry Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fabry Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fabry Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fabry Disease Treatment Market

A strategic analysis of the Fabry Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fabry Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Amicus Therapeutics Inc., Avrobio Inc., BioMarin, Biosidus S.A., Digestive Care, Inc., GlaxoSmithKline PLC, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Leadiant Biosciences, Inc., Nestle Health Science, Pfizer Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Fabry Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment, and Substrate Reduction Therapy.
• Based on Drugs, market is studied across Agalsidase Beta, Migalastat, and Pipeline Drugs.
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for messenger RNA as a treatment modality for Fabry disease
    • 5.1.1.2. Increasing number of clinical trials
    • 5.1.1.3. Growing incidences of genetic disorders and increasing awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of awareness about advancements with respect to treatments for Fabry disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development for the treatment of Fabry disease
    • 5.1.3.2. Increasing healthcare expenditure and improving infrastructure in emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations in adopting new technologies in certain countries
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Fabry Disease Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Chaperone Treatment
• 6.3. Enzyme Replacement Therapy
• 6.4. Organ-Specific Treatment
• 6.5. Substrate Reduction Therapy

7. Fabry Disease Treatment Market, by Drugs

• 7.1. Introduction
• 7.2. Agalsidase Beta
• 7.3. Migalastat
• 7.4. Pipeline Drugs

8. Fabry Disease Treatment Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral

9. Americas Fabry Disease Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Fabry Disease Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Fabry Disease Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amicus Therapeutics Inc.
• 2. Avrobio Inc.
• 3. BioMarin
• 4. Biosidus S.A.
• 5. Digestive Care, Inc.
• 6. GlaxoSmithKline PLC
• 7. Idorsia Pharmaceuticals Ltd.
• 8. ISU Abxis Co Ltd.
• 9. JCR Pharmaceuticals Co Ltd.
• 10. Leadiant Biosciences, Inc.
• 11. Nestle Health Science
• 12. Pfizer Inc.
• 13. Protalix Biotherapeutics Inc.
• 14. Sanofi S.A.
• 15. Takeda Pharmaceutical Company Limited